TGA / PMDA / NMPA · Asia-Pacific
sequence — TGA / PMDA / NMPA regulatory status
sequence regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 64 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 241502 | Phase 3 | Takeda | NCT02895945 |
| 54767414MMY2093 | Phase 2 | Janssen-Cilag International N.V | 2023-505792-71-00 |
| METFORMIN , Placebo 515 | Phase 2 | PARItec | 2023-508535-32-00 |
| 01-AMO-CLA-BIO-25 | Phase 1 | Zaklady FarmaFarmaceutyczne Polpharma | 2025-521718-24-00 |
| 01-DAP-BIO-24 | Phase 1 | Zaklady FarmaFarmaceutyczne Polpharma | 2024-520212-18-00 |
| 01/2023/Pozlab | Phase 1 | APREMEDA s.r.o | 2023-509841-12-00 |
| 1019/25 | Phase 1 | Tillomed Laboratories | 2025-522254-39-00 |
| 1062/25 | Phase 1 | Tillomed Laboratories | 2025-524035-39-00 |
| 300141 | Phase 1 | Haleon - Gebro | 2024-514198-23-00 |
| 845900241/0147/1 | Phase 1 | Anaxis Pharma | 2024-516942-21-00 |
| 987/24 | Phase 1 | Anaxis Pharma | 2024-515840-21-00 |
| 988/24 | Phase 1 | Anaxis Pharma | 2024-515841-41-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12410418 | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome | US |
| 12378560 | Sequence multiplicity within spherical nucleic acids | US |
| 12351839 | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences | US |
| 12319729 | Anti-Staphylococcus aureus specific antibody and nucleic acid encoding sequence thereof, and uses of the same | US |
| 12220446 | Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF | US |
| 12221483 | Fusion protein and nucleic acid encoding sequence thereof, and uses of the same | US |
| 12138301 | Compounds including a mutant KRAS sequence and a lipid and uses thereof | US |
| 12049479 | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom | US |
| 12012454 | Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same | US |
| 12006522 | Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene | US |
| 11993793 | Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene | US |
| 11898207 | Methods of isolating neoantigen-specific T cell receptor sequences | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of sequence?
sequence currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get sequence regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to sequence?
This spoke lists 64 published programs associated with sequence in our pipeline index.